Freenome, Inc. (FRNM) Stock Forecast Nov. 4, 2026
Analysis updated on Nov. 4, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
Freenome, Inc. (FRNM) stock forecast summary
Our AI scores Freenome, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Freenome, Inc. is a small-cap company with a market capitalization of $1.23B. It ranks number 14 by market capitalization among the 26 Services-Medical Laboratories issuers in our coverage with a current forecast. Its Current Ratio of 0.20x is the lowest of the 23 peers that report one.
For FRNM, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -50.0%, measured on 38 forecast dates between 2026-06-16 and 2026-08-06 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 37.0%, measured on 80 forecast dates between 2026-06-16 and 2026-10-05. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +5.1%, buy ≥ +3.3%, sell < +1.7%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-30 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, FRNM included.
FRNM price chart and AI forecast
How FRNM ranks among 4891 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Freenome, Inc. (FRNM) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Medical Laboratories peers listed below that report each metric.
Valuation & Market
| Metric | FRNM | Rank |
|---|---|---|
| Market Cap | $1.23B | 14/26 |
Profitability & Margins
| Metric | FRNM | Rank |
|---|---|---|
| ROA | -1.9% | 6/18 |
| ROIC | -5.3% | 8/21 |
Financial Health
| Metric | FRNM | Rank |
|---|---|---|
| Current Ratio | 0.20x | 23/23 |
| Working Capital | -$3M | 21/23 |
Cash Flow
| Metric | FRNM | Rank |
|---|---|---|
| Operating Cash Flow | -$910K | 12/24 |
Income Statement
| Metric | FRNM | Rank |
|---|---|---|
| Operating Income | -$4M | 10/23 |
| Net Income | -$2M | 5/18 |
Dividend & Shareholder Information
| Metric | FRNM | Rank |
|---|---|---|
| Shares Outstanding | 107M | – |
| Net Income Growth | -168.5% | 5/5 |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $740K | |
| Cash & Short-term Investments | $440K | |
| Total Liabilities | $7M |
FRNM quarterly financials and insider trading
Freenome, Inc. (FRNM) industry peers
Companies classified under the same SEC industry code as Freenome, Inc. (Services-Medical Laboratories): 27 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| FRNM Freenome, Inc. | $1.23B | |
| NTRA Natera, Inc. | $54.62B | |
| LH Labcorp Holdings Inc. | $28.74B | |
| DGX Quest Diagnostics Inc | $27.18B | |
| GH Guardant Health, Inc. | $23.48B | |
| CAI Caris Life Sciences, Inc. | $9.70B | |
| GRAL Grail, Inc. | $6.23B | |
| RDNT Radnet, Inc. | $5.78B | |
| BLLN Billiontoone, Inc. | $5.21B | |
| CDNA Caredx, Inc. | $4.52B | |
| VCYT Veracyte, Inc. | $3.94B | |
| CELC Celcuity Inc. | $3.38B | |
| FTRE Fortrea Holdings Inc. | $2.02B | |
| PSNL Personalis, Inc. | $1.68B | |
| LMRI Lumexa Imaging Holdings, Inc. | $1.08B | |
| CSTL Castle Biosciences Inc | $1.07B | |
| FLGT Fulgent Genetics, Inc. | $533M | |
| BDSX Biodesix Inc | $222M | |
| XGN Exagen Inc. | $203M | |
| BNR Burning Rock Biotech Ltd | $117M | |
| SERA Sera Prognostics, Inc. | $78M | |
| MDXH Mdxhealth Sa | $18M | |
| AMS American Shared Hospital Services | $8M | |
| ACON Aclarion, Inc. | $5M | |
| ADVB Advanced Biomed Inc. | $3M | |
| BGLC Bionexus Gene Lab Corp | $3M | |
| RNLXY Renalytix Plc | N/A |
Where FRNM sits on the market map
Freenome, Inc. (FRNM) stock news
Loading...
Freenome, Inc. (FRNM) stock forecast FAQ
What is the Freenome, Inc. (FRNM) stock forecast?
Our AI scores Freenome, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Freenome, Inc. stock predictions?
For FRNM, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -50.0%, measured on 38 forecast dates between 2026-06-16 and 2026-08-06 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 37.0%, measured on 80 forecast dates between 2026-06-16 and 2026-10-05. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Freenome, Inc. forecasts updated?
Freenome, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 4, 2026.
Which companies are Freenome, Inc.'s industry peers?
27 issuers in our coverage, FRNM included, share the SEC industry code Services-Medical Laboratories. The largest are: Natera, Inc. (NTRA), Labcorp Holdings Inc. (LH), Quest Diagnostics Inc (DGX), Guardant Health, Inc. (GH), Caris Life Sciences, Inc. (CAI), Grail, Inc. (GRAL).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.